Abstract
This document provides the latest recommendations for the evaluation of potential sperm, oocyte, and embryo donors, as well as their recipients, incorporating recent information about optimal screening and testing for sexually transmitted infections, genetic diseases, and psychological assessments. This revised document incorporates recent information from the US Centers for Disease Control and Prevention, the US Food and Drug Administration, and the American Association of Tissue Banks, with which all programs offering gamete and embryo donation services must be thoroughly familiar, and replaces the document titled ”Recommendations for gamete and embryo donation: a committee opinion,” last published in 2013.
Original language | English (US) |
---|---|
Pages (from-to) | 799-813 |
Number of pages | 15 |
Journal | Fertility and Sterility |
Volume | 122 |
Issue number | 5 |
DOIs | |
State | Published - Nov 2024 |
Funding
This report was developed under the direction of the Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Assisted Reproductive Technology (SART) as a service to its members and other practicing clinicians. Although this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. The Practice Committee and the Board of Directors of ASRM and SART have approved this report. This document was reviewed by ASRM members, and their input was considered in the preparation of the final document. The following members of the ASRM Practice Committee participated in the development of this document: Clarisa Gracia, M.D. M.S.C.E.; Jake Anderson; Rebecca Flyckt, M.D.; Micah Hill, D.O.; Tarun Jain, M.D.; Denny Sakkas, Ph.D.; Bruce Pier, M.D.; Anne Steiner, M.D. M.P.H.; Cigdem Tanrikut, M.D.; Belinda Yauger, M.D.; Karl Hnsen, M.D. Ph.D.; Suleena Kalra, M.D. M.S.C.E.; Elizabeth Ginsburg, M.D.; Jared Robins, M.D.; Chevis Shannon, Dr.P.H. M.B.A. M.P.H.; Jessica Goldstein, R.N. The Practice Committee acknowledges the special contribution of Jennifer F. Kawwass, M.D.; Anne Steiner, M.D. M.P.H.; Gena Shepherd, C.G.C.; Nirali Shah, M.D.; Andrea Braverman Ph.D.; Ali Ahmady, M.D.; William Petok, Ph.D.; Julia Woodward, Ph.D.; Danielle Kaplan, Ph.D.; and Molly B. Moravek, M.D. M.P.H.; in the preparation of this document. All committee members disclosed commercial and financial relationships with manufacturers or distributors of goods or services used to treat patients. Members of the Committee who were found to have conflicts of interest based on the relationships disclosed did not participate in the discussion or development of this document.
Keywords
- Sperm
- donor insemination
- donor screening
- oocyte
- quarantine
ASJC Scopus subject areas
- Reproductive Medicine
- Obstetrics and Gynecology